Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've made tons of money on CBIS. Anyone not interested in making money as it makes a huuuuge run should follow this advice.
The biggest obstacle right now is that Marijuana is Schedule 1 Drug. Under this classification it states that marijuana "has no currently accepted medical use". Which everyone knows is bogus. So I don't think the FDA can approve anything listed as schedule 1. However, The Huffington Post just wrote an article a couple weeks ago saying the DEA will decide on re-scheduling marijuana by July. It was only a matter of time but this is a lot sooner than I had anticipated. If they don't decide to do it now it will be done during a Clinton or Sanders presidency. But if it is done this July.....WATCH OUT! CBI$$$$
That currently have 3 drugs in R & D. CS-TATI-1 will be targeted to both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains.CS-S/BCC-1 –cannabinoid based extracts topically to their basal and squamous cell carcinomas. These patients have experienced shrinking and apparent eradication of their skin cancer lesions, backed by positive reports from their doctors. With these results, Cannabis Science is confident it can begin programs for over the counter (OTC) and prescription drug markets. CS-NEURO-1 for the Treatment of Neurobehavioral Disorders". The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety.
Can you clarify on when they will be behind bars? I see in 2009 you posted they would be behind bars. Have the FEDS issued a warrant for their arrest? Is the SEC investigating them?
Worked for me.
I've made tons of money investing in CBIS. And I will continue to make money this year as it makes a run. Thank you
Yep, After 7 years of false and misleading claims, I am still waiting for some evidence.
They have plenty of products and more rolling out. Everything they've said they have done or doing. Ive made a great deal of money investing in this company and the biggest gains have yet to come.
Do you have evidence to support this?
You Absolutely correct. Thank you Dabney for the Free shares out of your own pocket. You are doing an amazing job! Can't wait to see the designs for the new 360,000 sq ft facility! Cbis is going to make a lot of loyal shareholders a great deal of money!!!
Mr. Dabney is giving free money to the shareholders out of his own pocket, what a scammer. Congrats to the loyalists who will be receiving the free shares. Even bigger things coming...
Chump change. Profits will be in hundred millions once it's removed as schedule 1 and the FDA approves the 3 drugs they are developing. The train is leaving the station $$$
SO TRUE. Always been in under .05, out over .20.
Kubby will be on suicide watch after the stock goes through the roof and his former colleagues are billionaires. Dab-ney! Dab-ney! Dab-ney!
ALL ABOARD!! Woo Woo!!!!
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are cGMP compliant, surpassing high quality standard industrial and food processing requirements.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.
Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders" (CS-NEURO-1). The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders.
BASIS & PHILOSOPHY
Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.
To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.
SOME KEY PHYTOCANNABINOIDS ARE:
tetrahydrocannabinol (THC)
cannabidiol (CBD)
cannabigerol (CBG)
cannabichromene (CBC)
cannabinol (CBN)
These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.
The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.
Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.
The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.
The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.
While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.
These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.
As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.
Cannabis Science is one of the longest standing companies in the cannabis business.
We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.
The shorts are getting frustrated. Short selling down 58%.
http://www.examiner.com/article/q-a-with-raymond-c-dabney-a-seasoned-executive-leading-a-brand-new-industry
Pam Waits
Chicago Human Resources Examiner
Q & A with Raymond C. Dabney: A seasoned executive leading a brand new industry
A research and development medical cannabis company is as new now as web-based businesses were in the early ‘90s. So, what is it like to be running a company in this very early stage of a brand new industry?
I asked Raymond C. Dabney, President & CEO of Cannabis Science exactly that and here is what he had to say about being part of a historic time in this incredibly exciting industry.
What is Cannabis Science?
Cannabis Science is a forward thinking company specializing in cannabis formulation-based drug development and related consulting. We are working diligently to bring cannabinoid-based medicines to the forefront of the medical community’s attention by developing unique cannabis based approaches to treat the world’s most deadly illnesses.
Through drug development, medicinal characterization, and clinical research, our goal is to develop, produce, and commercialize innovative therapeutic approaches for treatment of illnesses caused by infections and age-related illness. Our initial focus is on skin cancers and neurological conditions with future endeavors to include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder, and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.
How many states allow legal medicinal cannabis?
Right now, 23 states permit medical cannabis to be used. What we are doing at Cannabis Science is creating a product line for physicians to prescribe to their patients with confidence. We are very proud of our efforts and our patient-portal of success stories continues to grow with more patients sharing their experiences using cannabis as an alternative medicinal method for short-term and chronic effective pain relief. It’s a very exciting time.
What are the most common health issues in which Cannabis can provide relief?
Cannabinoid-based medicines have been helpful in easing the symptoms of numerous conditions including Cancer, HIV-AIDS, Asthma, Tourettes and Glaucoma. Additionally, scientists recently found that topical cannabinoid-based preparations can be effective against MRSI, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments.
When you share your title and company name with strangers -- what reaction do you typically get?
Surprise and curiosity very quickly turns to keen interest. Everyone understands the crisis of pain and the traditional “go-to” solution of pills, which has the potential of leading to addiction. People want to know how Cannabinoid-based medicines can be applied, in controlled doses, through approved pharmaceutical manufacturing to help them and their loved ones. Finding new ways to deal with health issues is something everyone wants to know more about and supports.
How were you able to attract such formidable experts to your Board?
Medical professionals love being part of the unknown because they get to discover more answers and Cannabis Science provides the perfect platform. We are proud to have experts and visionaries helping us on our Scientific Advisory Board including former Assistant Surgeon General, Dr. Roscoe Moore, Jr. who served under three Presidents.
You were just appointed to the CFA Africa Healthcare Infrastructure Committee. Tell us about that.
I am honored to have been named as Vice Chair of this tremendously important committee. My company and foundation are committed to responding with urgency and seriousness of purpose to support long-term efforts to rebuild Africa's healthcare infrastructure along the priorities established by the Africa Healthcare Infrastructure Committee. This work will include education and training to replace workers lost in epidemics such as the HIV/AIDS and the Ebola epidemics, revitalization of agriculture, and leadership training. A healthy and vibrant Africa is good for everybody. Imagine the potential of untapped resources of Africa making their fair share contribution to the global economy, including in agricultural production, drug manufacturing and distribution. As CEO of Cannabis Science, we are seeking new regions to develop business for low-cost cannabis-based therapeutics, which could also meet the acute shortage of pain medications along with many other critical ailment treatments in Africa.
CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) Short Interest Decreased By 58.04%
Incorrect, there is zero evidence to support your claims. I can see the products on their website and through Jimi's Meds. I've spoken to the companies they've partnered with. I guess it's a mass conspiracy, lol. Lots of companies file there 10k late, it's perfectly normal. Wait until 1q financials are released, revenue is going up. 've been hearing for 7 years CBIS is about to go under. Jesus will return before this company folds.
CBIS= Many products rolling out this year, money starting to roll in, 40 billion dollar industry by 2020. Get in now or forever hold your peace!
It's 2016 and CBIS is alive and kicking! CAN....YOU....DIG IT!(shaq voice)
HOW IS KUBBY NOT IN JAIL?!
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
With the Special Board Meeting held on July 10, 2009, the Board has received and has accepted the resignation of Steven W. Kubby as a member of the Board of Directors.
The Board has received and has accepted the resignations of Ray Carr, Mary Ruwart and Lee Wrights from all previous positions held in the Company.
The Board hereby authorizes an internal investigation and review by counsel of Mr. Kubby's apparently fraudulent activities using the position he held as President & CEO as his authority to carry out these activities that damaged the Company and its shareholder value, including but not limited to:
a. Mr. Kubby's inappropriate and unauthorized signing of a financial and share agreement with Mary Ruwart and Ray Carr, which were not disclosed to nor approved by the Board, using unauthorized company shares as collateral or consideration for his personal gain.
b. Mr. Kubby's inappropriate and unauthorized signing of a financial and share agreement with a private party, which was not disclosed to nor approved by the Board, using unathorized company shares as collateral or consideration for his personal gain.
c. Mr. Kubby's inappropriate and unauthorized signing of a financial and share agreement with an independent financial group, which was not disclosed to nor approved by the Board, which could have significantly diluted and damaged shareholder interest.
d. Mr. Kubby's inappropriate and unauthorized acceptance of funds into a company account to which he had blocked and removed access by other officers and directors without approval or resolution.
e. Mr. Kubby's apparent inappropriate and unauthorized distribution of Company funds for his personal gain, while leaving essential obligations of the Company unmet.
f. Mr. Kubby's libelous accusation against the Company's Directors and a key consultant, while misrepresenting his own actions to the public and the media in a manner injurious to the Company's interests.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CANNABIS SCIENCE, INC.
Since former Cannabis Science Pres. and CEO Steve Kubby was hired by Cannabis Sativa Inc. The stock has dropped from 20 to 1.77. ROFL. This guy is such a joke. So glad Dabney fired that lying thief, he was a cancer to the company. It took a few a years but they finally recovered from the mess he left. Now things are really starting to BOOM! CBIS has been making GREAT moves the past year. GREAT MOVES!
The past 7 years are nothing but TRUTHS. There is no contradictory evidence that any of the companies news is false. As long as the stock keeps hitting 20-30cents with potential for higher gains, I'll keep buying low and selling high. Gonna make 100k again this year. Dabney for President!!!
Beware of pump/dump. Do your homework. CBIS is long term strong buy. New marijuana legalization and removal of schedule 1control substance will open many more doors for Cannabis Science. The future is very very bright
Everything on CBIS website is REAL. Every press release is REAL. They are the truth. Any company just starting off engaged primarily in research and development will have low assets and revenue. This year the products are starting roll out, partnerships are paying off, and they are expanding rapidly now. Get in on the ground floor.....next stop the PENTHOUSE!!!
CBIS has many products. Check their website. Check Jimi's Meds, there name is on all the products. Homework. They have many products in the research and development phase too. CBIS doesn't sell marijuana , it sells medicinal marijuana . homework. Is the 360,000 facility in Nevada not big enough? CBIS will be 20-30 cents in the fall, like it has done several times in the past. If anyone doesn't like money feel free not to invest in this AMAZING company. If you want to make bank get in on the ground floor. Thanks for the free shares Dabney!!!!
Like I said, the lady I spoke to said it will be available on the website in the next few weeks.
I spoke to someone with the company and they will be starting to accept documentation to receive the gifted shares over the next few weeks. Do you have a phone? Call 1-888-263-0832. Do you have Internet www.cannabisscience.com. It's so easy even a caveman can can do it. Dabney is class act! Paying hundreds of thousands out of his own pocket to the shareholders just shows how promising the future is. This new facilty is going to be cash cow. 40 billion dollar industry by 2020. Get in on the ground floor! Microsoft, Apple in 80s. Yahoo, Amazon, Google in the 90's. Cannabis Science in 2016!!!!
Money says it all, and I've made lots on this baby!!!!!! Can't wait for more big profits this fall as more states legalize!!!!
Say whatever you want about the company. THE BOTTOM LINE IS, this stock has hit 20-30 cents several times in the past. ESPECIALLY, in election years. With all the states set to pass legalization this fall, and the possibility of being removed a schedule 1 by Hilary or Bernie. That is enough to send the stock soaring back to these 20-30 cent levels or HIGHER. Anything else is meaningless and hasn't stopped the stock from going up in the past. Shorts are scared!
CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) Short Interest Decreased By 58.04%
http://www.riversidegazette.com/cannabis-science-incorporated-otcmktscbis-short-interest-decreased-by-58-04/
Last day to buy in and those gifted shares!!! And they won't be creating new shares to distribute, so no increase to float. Big gains today!
It's Unprecedented for A CEO to gift shares out of his own pocket. Even if it's just $1 worth for every $1,000. He would be giving out hundreds of thousands of dollars out of his own pocket. That speaks much louder than a dividend. He must really have confidence in the future of the company. Should be able to submit your proof of shares on the website in couple weeks. And I can't wait to see the designs for the new 360,000 sq ft facility in Nevada on the website. Expect an announcement soon regarding another facility being built in California. All these years of research, development and partnership forming are starting to pay off yuuuuge.
So glad they got rid of that fraud Kubby and the federal court canceled his shares. I've quadrupled my investment 3 times since then. This year will be #4. Dabney's the man! $1 a share by the end of the year. $10-$15 within 4 years! Industry is about to go boom!
COLORADO SPRINGS, Colo. - Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products announces Federal Court order for CBIS shares owned by Cannex Therapeutics controlled by Steve Kubby to be cancelled and re-issued to K&D. Both K&D and Cannabis Science denounce the "slanderous, malicious attacks" on the Company by its fired CEO Steve Kubby. Both parties are assessing additional legal action against Steve Kubby for his continued attacks against Cannabis Science, its shareholders, and the company's current management team as a safeguard to defend shareholder interest.
Cannabis Science and its former management group are working together to address Steve Kubby's false statements regarding the company, its transactions, its shareholders, and its current and future financial status. Currently, Cannabis Science lawyers are looking into possible legal action against Steve Kubby and those websites and blogs that knowingly enable his libelous statements and fraudulent behavior. Steve Kubby's attempts to discredit Cannabis Science, urging CBIS shareholders to sell their shares so that they can invest in his private company may raise some serious legal issues.
Yesterday, K&D President Charlie Stidham spoke to Cannabis Science management and stated, "I spoke to Steve Kubby and told him to never use my name without my consent and stop all the slanderous, malicious attacks against Cannabis Science and its team."
Stidham further stated, "I will exercise my legal options to cause these malicious, calculated attacks on the Company and myself to cease. Steve Kubby assured me he would not continue with the attacks against the Company."
Mr. Stidham also emphasized, "I'm very pleased with Dr. Robert Melamede and Richard Cowan being the control shareholders in Cannabis Science and the job they have done progressing the Company since Steve Kubby. Our group understands the real potential with Dr. Bob and Richard in control of Cannabis Science and we are very pleased to help them out anyway we can. These gentlemen are clearly the leaders in the industry, and they have been very clear with the path they are heading down. To see them build the company this quickly having so many opportunities by far overshadows over any single lozenge, which now is obviously just a minimal part of the Cannabis Science big picture."
Dr. Robert Melamede, Cannabis Science Inc. President and CEO, states, "Up until now, we have chosen to ignore Steve Kubby's attacks. We were giving him time to regain balance after having to remove him from his duties as President and CEO. However, his repeated attacks in an effort intended to destroy our credibility, at any cost, with his unethical statements and news releases have now raised questions from our investors, and have apparently affected our share price. Rather than answering individual inquiries we chose to clarify the situation with this press release."
Richard Cowan, Cannabis Science CFO, added, "It is important to reiterate that Cannabis Science is a fully reporting audited company, complying in every way with SEC regulations. Further, Cannabis Science fired Steve Kubby because of his questionable financial activities and his apparent inability to understand the basics of corporate governance for a public company. Steve Kubby's continued disregard of basic business practices and ethics underscores the correctness of our earlier decision to terminate him as President and CEO of Cannabis Science."
Cowan noted, "Regarding the recent court settlement order, Steve Kubby has completely misrepresented what has occurred. He claims that a summary judgment for K&D and against him was somehow a victory for him and that Cannabis Science 'no longer exists.' In fact, it had no bearing whatsoever on the legal status of Cannabis Science Inc. and its current management or business plans.
"Earlier, K&D Equity Investments Inc. amicably settled their differences with the current Cannabis Science management team. However, they did not settle with Cannex Therapeutics, Kubby's private company or with Kubby personally. Under the court order, Kubby was forced to give all of his shares in Cannabis Science to K&D and in return he is to be released from further actions against him from K&D on that matter. In order to demonstrate the patent absurdity of the situation, a few of the critical misrepresentations made by Mr. Kubby will be examined."
Cowan further stated, "The notion that Cannabis Science under one of the world's leading experts on cannabinoids would need anything from Steve Kubby is absurd. We are growing very rapidly through strategic acquisitions and partnerships with people who want to work with Dr. Robert Melamede. These developments give us great confidence in the future of Cannabis Science as a major player in the pharmaceutical industry providing alternative medicines in several distribution outlets such as dispensaries, over the counter nutraceutical and FDA approved medicines in several delivery formats such as sprays, creams, extracts, and strips based on whole plant based formulations."
Dabney just bought 20,000,000 shares, I guess he knows something you don't.
[url][/url][tag]http://ih.advfn.com/p.php?pid=nmona&article=70940257[/tag]
That everything is a lie and the company is fake, lol. All I know is I've made bank buying under 5 cents and selling for 20-30 cents on 3 different occasions. Looking forward to number 4
Spoke to someone over at Jimi Meds to find out more about the partnership. They said CBIS will be manufacturing their products in the new 360,000 facility in Nevada. So it's legit or Jimi's Meds (purplehazeproperties) is in on the conspiracy.
Purchased this stock 3 times for .05 or less and sold for .20 and higher. This will make number 4. I'm laughing all the way to the bank with them!
COO jus BOUGHT 20,000,000 shares. Beware of making large quantities of money!